Abstract
ALTHOUGH primary amyloidosis is refractory to most treatments, there have been some reports of limited but definite clinical improvements in patients treated with melphalan and prednisone.1 2 3 4 5 6 The improvements have included resolution of the nephrotic syndrome,7 a decrease in the size of the spleen and liver, normalization of the levels of hepatic enzymes,6 a decline in light-chain synthesis,3 and a reduction of amyloid in sequential liver-biopsy specimens.6 Since the first report (in 1962) of acquired factor X deficiency in amyloidosis,8 more than 30 cases have been described.9 10 11 12 13 14 15 16 Patients with this disorder may have life-threatening bleeding that is usually difficult to manage…
Original language | English (US) |
---|---|
Pages (from-to) | 1133-1135 |
Number of pages | 3 |
Journal | New England Journal of Medicine |
Volume | 316 |
Issue number | 18 |
DOIs | |
State | Published - Apr 30 1987 |
ASJC Scopus subject areas
- Medicine(all)